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In this issue of theEuropean Journal of Nuclear Medicine and
Molecular Imaging, Pfister et al. [1] evaluate the performance
of 18F-fluoroethylcholine (18F-FEC) and 68Ga-PSMA PET/
CT in patients undergoing salvage lymph node dissection
(sLND) for recurrent prostate cancer (PCa). The introduction
of novel imaging modalities and tracers has increased the de-
tection of oligometastatic PCa recurrence, potentially justify-
ing the use of sLND rather than a systemic approach. The
present study is premised on the notion that radiopharmaceu-
tical agents can be useful for guiding surgical procedures in
cases of predominant nodal recurrence of PCa. This is a topic
of great interest to urologists, radiologists and nuclear medi-
cine physicians. What evidence must we consider for the use
of sLND? Could extended LND rather than sLND during
radical prostatectomy (RP) improve patient survival? What
is the best imaging modality for ensuring appropriate
treatment?
These closely related questions are important because they
prompt us to examine the value of clinical trials in the area of
sLND in PCa. The literature is lacking in both randomized
trials comparing sLND with a control group treated with cur-
rent best practice and prospective case–control studies evalu-
ating the impact of PET imaging for the detection of lymph
node metastases before or after RP. The Bscientific run^ to the
best imaging modality and highest-performing tracer is justi-
fied only if they provide a survival benefit and improved qual-
ity of life for patients with oligometastatic PCa.
In addressing this issue, therefore, key points to consider in
the design of future studies include (1) selection of the patient
population, (2) previous therapies and ongoing androgen ther-
apy, (3) extension of sLND, (4) the definition of endpoints and
outcomes, (5) a comparison of different imaging modalities in
the same population, and (6) whom to randomize—for exam-
ple, the patients, the surgeons, or the imaging technologists?
In the study by Pfister et al. [1], 66 patients were retrospec-
tively evaluated: 38 underwent 18F-FEC and 28 underwent
68Ga-PSMA PET/CT prior to sLND. Differences between
the two populations must be considered, including demo-
graphic characteristics, primary treatments, and follow-up
management. In our opinion, the selection of patients is the
key driver for the trial. Only patients with well-defined treat-
ment of the primary tumor should be included.
The extension of lymphadenectomy during RP should be
defined, even though the role of pelvic lymph node dissection
remains one of the most controversial areas in the manage-
ment of clinically localized PCa. However, recent advances in
our understanding of tumor biology and the introduction of a
new PCa classification system [2] should enable better strati-
fication of patients and should provide information about the
best treatment strategy.
Any systemic or combination therapy should be avoided
before sLND procedures. This is of pivotal importance, given
the potential effects of hormone or radiation therapy on PET/
CT performance. In our experience, patients with hormone-
sensitive PCa and those with castration-resistant cancer
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undergoing androgen deprivation therapy and treatment with
new anti-hormonal agents (e.g. abiraterone acetate or
enzalutamide), respectively, demonstrate a significant reduc-
tion in radiolabeled choline PET/CT uptake in the lymph
nodes after the administration of drugs (Fig. 1). In addition,
careful selection of the time from primary treatment to sLND
and the PSA cutoff before salvage surgery is critical, because
they will affect the sensitivity and specificity of nuclear imag-
ing modalities. In the study by Pfister et al. [1], PSA values
ranged from 0.04 to 8.4 ng/mL, with a median of 2.7 and
2.35 ng/mL, respectively, for 18F-FEC and 68Ga-PSMA.
However, PSA alone cannot predict a positive PET/CT, be-
cause the sensitivity and specificity of radiolabeled choline in
these patients is increased in cases of low PSA doubling time
and high PSA velocity [3].
Accuracy is a frequent endpoint in diagnostic studies.
However, a series of different outcomes should be addressed
in PCa patient candidates for sLND. For example, the current
literature shows that some patients benefit from sLND, with
approximately 9–19 % remaining free from biochemical re-
currence, and approximately 26–34 % remaining free from
clinical recurrence [4, 5]. However, these data indicate that
the benefit of sLND in the majority of cases is prolonging
survival and/or postponing hormone therapy, but not achiev-
ing a complete cure. Indeed, whether these patients would
have died from PCa without the removal of the lymph node
metastases is unknown. Information about the site of nodal
relapse may be suboptimal, particularly for sacral and retro-
peritoneal regions. Extended retroperitoneal lymph node dis-
section is likely the only approach for limiting the effect of the
Will Rogers phenomenon. The risk of surgical complications
is obviously also an ethical concern. Although Pfister et al. [1]
reported no data about site/region accuracy for either 18 F-FEC
or 68Ga-PSMA PET/CT, reports available in the literature
indicate that the accuracy of radiolabeled choline for the de-
tection of retroperitoneal lymph node recurrence ranges from
20 to 40 % [6–8], thus guiding the use of extended sLND in
only a small percentage of patients.
Another important issue is the comparison of different im-
aging modalities, such as diffusion-weighted magnetic reso-
nance imaging (DW-MRI) and PET/CT with radiolabeled
choline or 68Ga-PSMA, in the same population. The study
by Pfister et al. [1] was performed in different study popula-
tions. Although patient characteristics were similar, certain
biological tumor features would have affected the accuracy
of both radiopharmaceutical agents. Most published papers,
however, have discussed the performance of DW-MRI in
lymph node staging in PCa before primary treatment. The
reliability of the technique for detecting clinical lymph node
relapse after primary treatment is still unknown, and therefore
warrants further investigation [3].
Finally, several medical reasons can be considered as con-
founders, both surgical (i.e. individual surgical volume, exper-
tise and commitment to performing sLND) and imaging issues
(i.e. blinded analysis, reading experience and reproducible
methodology).
In conclusion, while a prospective randomized trial may
provide definitive answers to the abovementioned Bclinical
questions^ concerning the role of sLND, conversely, it could
lead to misleading conclusions. Therefore, it is extremely im-
portant to adopt different treatment regimens by considering
the biology and behavior of PCa. In this regard, careful patient
Fig. 1 a A 67-year-old man with PCa treated by radical prostatectomy
and lymph node dissection (pT3bN1; GS: 9; positive margins). Serial
monthly PSA (0.56 ng/mL- > 2.37 ng/mL-> 3.03 ng/mL) demonstrated
biochemical failure, with significant uptake of 18 F-fluoroethylcholine in
the abdominal-pelvic lymph node on PET/CT images (left), and thus
treatment with LH-RH agonists was started. Six months after the start
of treatment, PET/CT was negative (right). b A prostate cancer patient
with increased PSA level (36.80 ng/mL) during hormone therapy.
Significant uptake of choline at the lumbar lymph nodes was
demonstrated (left). The patient was treated with abiraterone acetate. A
PET/CT with 18 F-fluoroethylcholine (right) 3 months after the start of
therapy showed a good metabolic response (PSA: 12.97 ng/mL)
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selection, novel biomarkers, and developments in nuclear
medicine will certainly help in resolving these issues.
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